These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 16549404)

  • 1. ADHD drugs and cardiovascular risk.
    Nissen SE
    N Engl J Med; 2006 Apr; 354(14):1445-8. PubMed ID: 16549404
    [No Abstract]   [Full Text] [Related]  

  • 2. ADHD drugs and cardiovascular risk.
    Rappley MD; Moore JW; Dokken D
    N Engl J Med; 2006 May; 354(21):2296-8; author reply 2296-8. PubMed ID: 16729375
    [No Abstract]   [Full Text] [Related]  

  • 3. To box OR NOT TO box.
    Newstadt M
    J Ky Med Assoc; 2006 Aug; 104(8):344-5. PubMed ID: 16939037
    [No Abstract]   [Full Text] [Related]  

  • 4. Debate over warnings for ADHD stimulants.
    Child Health Alert; 2006 Apr; 24():1. PubMed ID: 16673500
    [No Abstract]   [Full Text] [Related]  

  • 5. ADHD drugs and cardiovascular risk.
    Anders T; Sharfstein S
    N Engl J Med; 2006 May; 354(21):2296-8; author reply 2296-8. PubMed ID: 16723628
    [No Abstract]   [Full Text] [Related]  

  • 6. Medications for attention deficit hyperactivity disorder: cardiovascular concerns.
    Wooltorton E
    CMAJ; 2006 Jul; 175(1):29. PubMed ID: 16772535
    [No Abstract]   [Full Text] [Related]  

  • 7. [Medication for ADHD and the risk of cardiovascular mortality].
    Langendijk PN; Wilde AA
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1713-4. PubMed ID: 16924941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulant medications and attention deficit-hyperactivity disorder.
    Cohen AL; Jhung MA; Budnitz DS
    N Engl J Med; 2006 May; 354(21):2294-5. PubMed ID: 16723627
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA-approved drugs to treat ADHD.
    J Psychosoc Nurs Ment Health Serv; 2012 Mar; 50(3):11-2. PubMed ID: 22390784
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder.
    Newcorn JH; Donnelly C
    Mt Sinai J Med; 2009 Apr; 76(2):198-203. PubMed ID: 19306385
    [No Abstract]   [Full Text] [Related]  

  • 11. US senator alleges FDA tried to prevent Adderall XR withdrawal in Canada.
    Eggertson L
    CMAJ; 2005 Mar; 172(7):865. PubMed ID: 15758187
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA ponders cardiovascular risks of ADHD drugs.
    Young D
    Am J Health Syst Pharm; 2006 Mar; 63(6):492-4. PubMed ID: 16522874
    [No Abstract]   [Full Text] [Related]  

  • 13. [Sympathomimetics in ADHD. Cardiovascular risks, FDA warns].
    Ostman-Smith I; Dellborg M
    Lakartidningen; 2007 Apr 25-May 1; 104(17):1307. PubMed ID: 17547274
    [No Abstract]   [Full Text] [Related]  

  • 14. Stimulants and sudden death: what is a physician to do?
    Wilens TE; Prince JB; Spencer TJ; Biederman J
    Pediatrics; 2006 Sep; 118(3):1215-9. PubMed ID: 16951018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulant treatment of ADHD and risk of sudden death in children.
    Vitiello B; Towbin K
    Am J Psychiatry; 2009 Sep; 166(9):955-7. PubMed ID: 19528196
    [No Abstract]   [Full Text] [Related]  

  • 16. Hypertension due to anorectic agent.
    Shapiro SR
    N Engl J Med; 1969 Jun; 280(24):1363. PubMed ID: 5783669
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent developments in direct consumer advertising of attention disorder stimulants and creating limits to withstand constitutional scrutiny.
    Strawn MN
    J Contemp Health Law Policy; 2003; 19(2):495-520. PubMed ID: 14748255
    [No Abstract]   [Full Text] [Related]  

  • 18. Hidden amphetamines: from smoking cessation to diabetes.
    Prescrire Int; 2004 Feb; 13(69):18-20. PubMed ID: 15055218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
    Perrin JM; Friedman RA; Knilans TK; ;
    Pediatrics; 2008 Aug; 122(2):451-3. PubMed ID: 18676566
    [No Abstract]   [Full Text] [Related]  

  • 20. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.